The 2023 turnover stands at €19.8M compared to €14.3M in 2022, an increase of 38%.
Gross margin
[1]
reaches €5.2M in 2023, or 26% of turnover compared to €4.3M for the 2022 financial year.
The company has controlled its operating costs in 2023, stable compared to the previous financial year.
The 2023 operating result amounts to a (€1.3M) loss, an improvement of €1.3M compared to the 2022 financial year.
The company recorded exceptional expenses, following resolutions of past disputes for €1M, thus the consolidated net result shows (€2.4M) losses for the 2023 financial year.
|
Consolidated income statement in €M |
2023 |
2022 |
Var M€ |
Var % |
|
Turnover |
19.78 |
14.29 |
5.49 |
38% |
Gross margin and other exploding products | 5.24 | 4.26 | 0.98 | 23% |
|
As a % of turnover |
26% |
30% | ||
Operational Charges | 6.58 | 6.90 | -0.32 | -5% |
|
Operating profit |
-1.34 |
-2.64 |
1.30 | |
|
Operating profit in % |
-7% |
-18% | ||
Exceptional and Financial Results | -1.00 | 1.12 | -2.12 | |
IS | -0.06 | 0.01 | -0.07 | |
|
Consolidated net income |
-2.40 |
-1.51 | -0.89 |
Balance Sheet Items
|
Balance sheet in €K |
2023 |
2022 |
Balance sheet in €K |
2023 |
2022 | |
Acquisition difference | 3,814 | Equity & int mino | 619 | -29 | ||
other assets | 1,111 | 749 | R&C provisions | 1,106 | 810 | |
Stocks | 3,681 | 3,308 | Loans | 11,551 | 7,073 | |
Customers, Receivables and advances | 7,183 | 3,263 | Supplier debts & related accounts | 9,092 | 8,869 | |
Availability | 10,349 | 12,062 | Other debts and accruals | 3,770 | 2,659 | |
|
Total |
26,138 |
19,382 |
Total |
26,138 |
19,382 |
In 2023, the company recognized two goodwill, one linked to the acquisition of Medical Devices Venture and the other to the purchase of Elexo by the subsidiary Logic Instrument. The stock remained stable in absolute value despite the 38% increase in turnover and the integration of Elexo. Customer accounts increased significantly, largely linked to the integration of Elexo at the end of 2023. Cash stood at €10.3 million compared to €12.1 million, the impact is mainly linked to disbursement in equity following the acquisition of Elexo. Borrowings increased by €4.4 million, including €2.6 million contracted for the purchase of Elexo by Logic Instrument and €1.6 million by Elexo in a Participatory Recovery Loan to support future growth.
Importants events
At the end of October 2023, Logic Instrument purchased the company Elexo from ATOS, included in the consolidated accounts for the months of November and December 2023.
Medical Devices Venture was delisted from Euronext Access following a request from ARCHOS at the end of 2023.
Outlook
The group now plans to reach €40 million in consolidated turnover in 2024 and approach break-even in operating income.
The group intends to continue to develop professional sales of mobile solutions for defense, industry and services but also to accelerate with Medical Devices Venture the deployment of its subsidiaries, Dextrain, Poladerme, Domisanté and MDV IT.
For the consumer electronics part, ARCHOS will unveil its new range of tablets in May 2024.
The company is also publishing today a press release concerning two capital increases aimed at repaying in advance the dilutive instruments in circulation as well as the balance of the company’s debt to the management trust established by the company on December 21, 2023, this which would make it possible to stop any further dilution in the short/medium term and to stabilize the company’s shareholding.
Contact Investors
Loïc Poirier – Chairman and CEO – [email protected]
————————————————– ————————————————– ————————————————
About ARCHOS
ARCHOS, an expert in mobile solutions, has constantly revolutionized this market both in the consumer electronics sector and in B to B with its subsidiary LOGIC INSTRUMENT. The French brand was the first to offer Google Android tablets in 2009. ARCHOS launched a MedTech division in 2021, Medical Devices Venture, which will bring together several start-ups. With a head office in France and offices in Europe and Asia, ARCHOS has established itself as a key pan-European player, listed on the Euronext Growth Paris market, ISIN Code: FR001400K061. archos.com
[1]
Including other operating income
This publication has the “🔒 Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
mZqaZZVmZ5fGxnBwk5tmbmRlmmdjkpLGbmmal2ZpaMqVZ59glW2Vb5iYZnFlm2Zu
– To control this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Press release on accounts, results
Full and original press release in PDF format:
https://www.actusnews.com/news/84618-18-mars-2024.pdf
© Copyright Actusnews Wire
Receive future company press releases free of charge by email by subscribing to www.actusnews.com